Fig. 5: Clinical significance of BRPF1 expression.
From: Exploiting epigenetic targets to overcome taxane resistance in prostate cancer
A BRPF1 mRNA levels were analyzed in the Pan-Cancer Analysis dataset (ICGC/TCGA, Nature 2020) from cBioPortal. Kaplan-Meier plot showing the comparison of patient survival based on BRPF1 expression levels. The patients were classified into Low BRPF1 and High BRPF1 groups based on the expression median. The distribution of BRPF1 expression (B) across different cancers and (C) sample types. The numbers within the column bars correspond to the sample size. D BRPF1 mRNA levels in clinical PCa specimens were examined for their correlation with neoplasm status (Prostate Adenocarcinoma, TCGA, PanCancer Atlas), recurrence (Prostate Adenocarcinoma, TCGA, Firehose Legacy), sample type (Prostate Adenocarcinoma, Fred Hutchinson CRC, Nat Med 2016) (E) Gleason score (Prostate Adenocarcinoma, TCGA, Firehose Legacy), tumor stage (Prostate Adenocarcinoma, TCGA, Firehose Legacy), (F) therapy outcome (Prostate Adenocarcinoma, TCGA, Firehose Legacy), and taxane exposure status (Metastatic Prostate Adenocarcinoma, SU2C/PCF Dream Team, PNAS 2019). The results were presented as scatter plots.
